Biotech · Private company
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Track this companyFree. Adds Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) to your Dealase workspace and tells you when its record changes.
Clinical trials63 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- BelzutifanPhase 2 · Renal Cell Carcinoma (RCC)ClinicalTrials.gov · fetched Nov 12, 2026
- BelzutifanPhase 2 · VHL - Von Hippel-Lindau SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- CabozantinibPhase 2 · Renal Cell Carcinoma (RCC)ClinicalTrials.gov · fetched Nov 12, 2026
- MK-3795Phase 2 · VHL Gene MutationClinicalTrials.gov · fetched Nov 12, 2026
- BelzutifanPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- BezlutifanPhase 1 · ccRCCClinicalTrials.gov · fetched Nov 12, 2026
- CabozantinibPhase 1 · ccRCCClinicalTrials.gov · fetched Nov 12, 2026
- MK-3795Phase 1 · ccRCCClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 1 · ccRCCClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 27, 2018ClinicalTrials.gov NCT03634540 · fetched Nov 12, 2026
- A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)PHASE2 · ACTIVE_NOT_RECRUITING · started May 2, 2018ClinicalTrials.gov NCT03401788 · fetched Nov 12, 2026
- A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) TabletsPHASE1 · COMPLETED · started Feb 23, 2018ClinicalTrials.gov NCT03445169 · fetched Nov 12, 2026
- HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent GlioblastomaPHASE2 · COMPLETED · started Sep 14, 2017ClinicalTrials.gov NCT03216499 · fetched Nov 12, 2026
- MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)PHASE2 · COMPLETED · started Apr 24, 2017ClinicalTrials.gov NCT03108066 · fetched Nov 12, 2026
- A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)PHASE1 · ACTIVE_NOT_RECRUITING · started Nov 25, 2014ClinicalTrials.gov NCT02293980 · fetched Nov 12, 2026